“Atrial fibrillation in patients taking ibrutinib poses a unique challenge as the cumulative bleeding risk from the ibrutinib‐related antiplatelet effects added to the anticoagulation can be dangerously high, as confirmed by clinical trials which found unacceptable bleeding rates when ibrutinib was used in combination with vitamin K antagonists.”